A chemist based at the University of Copenhagen has just taken out a patent for a drug that can make previously multidrug-resistant bacteria responsive to antibiotics once again.
Jørn Bolstad and his chemist colleagues hope that the substance will soon be able to tackle the tremendous problems associated with multidrug resistant tuberculosis (MDR-TB). But first, they need to find investors interested in getting the substance onto the market.
Before the development of penicillin, people dropped like flies in response to minor infections: in the lungs, in small cuts. Even pimples could grow to boils that killed. But one of the main killers prior to the discovery of antibiotics was tuberculosis.
The deadly infectious disease that typically affects the lungs has returned. It has developed a resistance to the majority of antibiotics that would otherwise kill the tuberculosis bacteria. Currently, the disease does not pose an imminent threat to Denmark or the West. However, resistant strains of the bacteria are nearing the region’s borders. This is one of the reasons why doctors around the world are busy trying to solve the problem of drug resistance.
The bacteria shed killing substances
While those bacteria that have developed a resistance remain vulnerable to antibiotics, they have developed an ability to shed bacteria killing substances before any damage is done to them. Colloquially, this is referred to as pooping the substance out, but the scientific formulation is that these bacteria activate an efflux pump.
Jørn Bolstad Christensen has isolated a substance able to block the efflux pump so that an antibiotic remains in bacteria until the bacteria dies.
You could say that we cure bacteria of their resistance, and slay them with antibiotics, explains Associate Professor Jørn Bolstad Christensen.
From antipsychotic to killing bacteria
Working with doctors Jette Kristiansen from the University of Southern Denmark and Oliver Hendricks from the King Christian X’s Hospital for Rheumatic Diseases in Gråsten, Denmark, Jørn Bolstad Christensen discovered that Thioridazin, an antipsychotic drug, was able to kill bacteria without any noticeably harmful effects upon humans. Still, the chemists had an idea that could make the substance more benign.
We now have a substance that is able to block the bacteria’s efflux pump. At very most, recipients of the medication may become slightly sluggish. This is also because very small doses are needed to affect the bacteria, says Jørn Bolstad Christensen.
Researchers hope for quick approval
Because Thioridazin is an approved drug, the research team hopes that the new anti-resistance medication, JEK 47, will be approved without going through the entire process that new pharmaceuticals are typically subjected to. If this is the case, JEK 47 will most likely be a cheap medication that a pharmaceuticals manufacturer could release quickly. However if an investor does not show interest, Christensen is certain about his next step.
The Latest on: Antibiotic resistance
via Google News
The Latest on: Antibiotic resistance
- Superbugs: Exploring Auckland's sewers to study antibiotic resistanceon May 13, 2020 at 10:03 am
Scientists will delve into Auckland's sewer network to test the antibiotic resistance of superbugs in the community.
- Resistant superbugs are 'hidden danger' in the coronavirus crisis: Merckon May 13, 2020 at 3:08 am
The coronavirus crisis has a "hidden danger" where infected patients are prone to developing "superbugs", which are developing antibiotic resistance faster than what is being produced to fight them, ...
- COVID-19 Antibiotic Overuse Puts Stewardship Efforts at Riskon May 12, 2020 at 1:42 pm
Many COVID-19 patients are getting antibiotics even when the drugs are unlikely to help, raising concerns about patient safety and antibiotic resistance, experts told MedPage Today. That practice ...
- Antibiotic resistance may rise after COVID-19, as doctors struggle to treat secondary infectionson May 8, 2020 at 9:55 am
Doctors around the world are struggling to cure secondary illnesses patients contracted while battling coronavirus. Wired contributor Maryn McKenna joined CBSN to explain why this may contribute to ...
- Engineering natural selection in microbes has implications for biofuel production, addressing antibiotic resistanceon May 8, 2020 at 6:56 am
Scientists who study adaptation—or edit the genes of organisms—know the limitations inherent in conventional approaches to mutation that offer little opportunity to target individual genes without ...
- Antibiotic resistance is a dangerous consequence of our tendency to overuse drugson May 7, 2020 at 7:01 pm
Antibiotic resistance makes infections, like UTIs, more difficult to treat, and increases the risk of deadly infections in hospitals.
- Positive Facts One Should Know About Antibiotic Resistance Market for 2020on May 7, 2020 at 9:50 am
The antibiotics are the antimicrobial substance that is used to fight against the bacterial infection. Antibiotics are also used to cure several conditions including strep throat, urinary tract ...
- Why bacteria's resistance to antibiotics is a problem in a viral pandemicon May 6, 2020 at 9:28 am
Each year a particular kind of infection kills more than 35,000 people in the United States. Those deaths are caused by antibiotic-resistant bacteria.
- Rapid identification of pathogens, antibiotic resistance genes and plasmids in blood cultures by nanopore sequencingon May 6, 2020 at 2:10 am
Most studies on sepsis and BSIs report an increasing incidence over the last two decades 3, particularly among the immunocompromised, multimorbid, and elderly patients, or due to failure of empiric ...
- Antibiotic Resistance: The Patient Perspectiveon May 6, 2020 at 1:18 am
We discuss the impact of antibiotic-resistant infections on everyday life and the work that is being done to overcome this issue with Antibiotic Research UK.
via Bing News